Sagimet Biosciences Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Sagimet Biosciences Inc. (SGMT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $5.38 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-05-12
- Sagimet Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.38, a 14.23% increase year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.71, a 14.05% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.48.
- Sagimet Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $4.23, a 68.69% decline from fiscal 2023.
- Sagimet Biosciences Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $13.51.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-03-31 | $5.38 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | $4.83 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $4.83 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $4.71 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $4.23 10-K · filed 2025-03-12 | |||
| 2024-09-30 | $4.43 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $4.62 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $5.48 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $13.51 10-K · filed 2024-03-25 | |||
| 2023-09-30 | $13.51 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |